Category News

GC Aims for Turnaround with THB 4.5 Billion Annual Growth and $300 Million EBITDA by 2030

GC Aims for Turnaround with THB 4.5 Billion Annual Growth and $300 Million EBITDA by 2030

GC Targets Turnaround with Strategic Focus on Cost Reduction and Revenue Growth PTT Global Chemical Public Company Limited has unveiled its ambitious strategic roadmap to overcome industry challenges and achieve sustainable growth. In response to the global economic volatility and…

Read MoreGC Aims for Turnaround with THB 4.5 Billion Annual Growth and $300 Million EBITDA by 2030
ICR and Royal Marsden Study Highlights ctDNA Testing for Early-Stage Breast Cancer Recurrence

ICR and Royal Marsden Study Highlights ctDNA Testing for Early-Stage Breast Cancer Recurrence

Personalis and Royal Marsden Study Advances Early-Stage Breast Cancer Detection with NeXT Personal® ctDNA Test ICR and Royal Marsden Study Highlights ctDNA Testing Introduction: Advancements in Breast Cancer DetectionPersonalis, Inc. has partnered with renowned researchers from The Institute of Cancer…

Read MoreICR and Royal Marsden Study Highlights ctDNA Testing for Early-Stage Breast Cancer Recurrence
Celltrion's Avtozma® (CT-P47) Biosimilar Receives European Commission Approval

Celltrion’s Avtozma® (CT-P47) Biosimilar Receives European Commission Approval

Celltrion’s Avtozma® (CT-P47) Biosimilar Receives European Commission Approval Celltrion has announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a biosimilar to RoActemra® (tocilizumab). Avtozma® is approved for all indications of its reference product, RoActemra®, including…

Read MoreCelltrion’s Avtozma® (CT-P47) Biosimilar Receives European Commission Approval